COLLABORATION AGREEMENTS (Tables)

3 Months Ended

Mar. 31, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Revenue from Collaborators

The following table summarizes our total condensed consolidated net revenues from collaborators, for the periods indicated, in thousands:

	Three Months Ended March 31,
Description	2019		2018
Sanofi Genzyme	$	4,117	$	18,853
The Medicines Company		1,745		1,295
Vir Biotechnology		928		1,242
Other		213		509
Total net revenues from collaborators	$	7,003	$	21,899

Balance and Change in Receivables and Contract Liabilities Related to Collaboration Agreements

The following table presents the balance of our receivables and contract liabilities related to our collaboration agreements at March 31, 2019 and December 31, 2018, in thousands:

	At March 31, 2019		At December 31, 2018
Receivables included in “Accounts receivable, net”	$	11,723	$	5,625
Contract liabilities included in “Deferred revenue”		3,026		3,954

During the three months ended March 31, 2019, we recognized the following revenue as a result of the change in the contract liability balances related to our collaboration agreements, in thousands:

Revenue recognized in the period from:	Three Months Ended March 31, 2019
Amounts included in contract liability at the beginning of the period	$	928

Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements

The following table provides the research and development expenses incurred by type that are directly attributable to our collaboration agreements by our collaboration partners for the periods indicated, in thousands:

	Three Months Ended March 31,
	2019						2018
	Sanofi Genzyme		MDCO		Vir		Sanofi Genzyme		MDCO		Vir
Research and development
Clinical trial and manufacturing	$	4,826	$	1,612	$	294	$	10,523	$	641	$	554
External services		135		10		236		2,673		—		688
Other		59		50		129		509		—		200
Total research and    development expenses	$	5,020	$	1,672	$	659	$	13,705	$	641	$	1,442